The US Food and Drug Administration and the American Society for Clinical Oncology’s fourth annual workshop on clinical outcome assessments in cancer clinical trials introduced an estimand framework that is designed to ensure “that the research question we want to answer is answerable once the data is collected.”
The estimand framework “provides a structure so that all stakeholders are speaking a common language,” FDA materials summarized
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?